尊龙凯时
About us
尊龙凯时:Our Values
尊龙凯时:Development Milestone
Products
尊龙凯时:Product List for API
尊龙凯时:Recommended API
尊龙凯时:Product list for Chemicals and Intermediates
Product list for Chemicals and Intermediates
News
尊龙凯时:Contract Manufacturing
尊龙凯时:API and Pharmaceutical Intermediates
尊龙凯时:OTC and Generics
尊龙凯时:Investor Relation
PERIODIC REPORT
尊龙凯时:INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
尊龙凯时:Contact Us
About us
News
尊龙凯时:Investor Relation
Products
尊龙凯时:Contract Manufacturing
尊龙凯时:Contact Us
Investor Relation
Investor Relation
尊龙凯时:PERIODIC REPORT
尊龙凯时:INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
Final Dividend for the Year Ended 31 December 2023
2024-03-28
Proposed Amendments to the Articles of Association
2024-03-28
Proposed Change of Auditors
2024-03-28
Announcement Notice of Board Meeting
2024-03-14
Overseas Regulatory Announcement-Announcement on Ibuprofen Sustained Release Capsules Obtaining the Drug Registration Certificate
2024-03-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
2024-03-01
Announcement on Prednisone Having Obtained the Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient
2024-02-28
Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
2024-02-19
Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
2024-02-19
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
2024-02-01
<
...
5
6
7
8
9
10
11
...
>